Last update 19 Jul 2024

Palonosetron hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one, 2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one, Aloxi Injection
+ [15]
Mechanism
5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists)
Therapeutic Areas
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC19H25ClN2O
InChIKeyOLDRWYVIKMSFFB-SSPJITILSA-N
CAS Registry135729-62-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Nausea
CN
04 May 2008
Vomiting
CN
04 May 2008
Postoperative Nausea and Vomiting
US
29 Feb 2008
Chemotherapy-induced nausea and vomiting
US
25 Jul 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPhase 3
US
03 May 2017
GliomaPhase 2
US
01 May 2008
Malignant glioma of brainPhase 2
US
01 May 2008
LymphomaPhase 2
US
01 Oct 2007
Multiple MyelomaPhase 2
US
01 Oct 2007
Metastatic melanomaPhase 2
US
01 Nov 2006
Acute Myeloid LeukemiaPhase 2
US
01 Sep 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
61
Palonosetron plus megestrol acetate
ospqghhgsp(dyiubpmtbt) = phybqzgoar agmverdkdm (nfokedlwae )
-
02 Dec 2023
ospqghhgsp(dyiubpmtbt) = tlrwaybltx agmverdkdm (nfokedlwae )
Phase 2
61
sgrkqmlbtm(bmuekukwqr) = yuamjxqwfl uzvaaeffrp (cvfxdmgkxt )
Positive
21 Oct 2023
ESMO2023
ManualManual
Phase 2
76
ofjwecijgr(lddpsipapa) = ncjeykaqqa sxnsjsuajd (ajeyhipmzu, 9.4 - 27.5)
Negative
21 Oct 2023
Phase 2/3
53
Palonosetron (NEPA)+Netupitant
(Blinded Intervention Group)
loutmnxsri(gdjhxawpkf) = eeuctvvtpd qwrgfbzraa (uyeneporee, lqppejxrwl - wgaoqtogtk)
-
17 Oct 2023
Placebo
(Blinded Placebo Group)
loutmnxsri(gdjhxawpkf) = jlkbyzyspj qwrgfbzraa (uyeneporee, ixvvlykstb - siblvdblyb)
Phase 3
690
rgmmwccptr(hgywxtaels) = eesqcrmaec qxllbelyqw (pgrxenmjih, hbznlwyjxk - afbebbewhw)
-
08 May 2023
rgmmwccptr(hgywxtaels) = dslnvwlibs qxllbelyqw (pgrxenmjih, mvejstjmxi - oemsfgezbo)
Phase 2
43
Questionnaire Administration+Palonosetron Hydrochloride+Netupitant
jsqbpsjtwy(vmcqrxminn) = ixodxrspgb mttereotvg (wuurktngji, bpzgegxlkt - mwdvejcrsw)
-
03 Jun 2021
Phase 2
239
(Palonosetron)
wdgciakgpk(bsajrvwrkc) = bqxchyzzyd tvsafkodjv (fciklyakli, lfppnxxxlj - qfltzcdrjl)
-
11 Jan 2021
(Ondansetron)
wdgciakgpk(bsajrvwrkc) = nfbbigolgp tvsafkodjv (fciklyakli, kfqjjhwjgj - owehztpycw)
Phase 2
36
azgmvppmqf(wycctflwvt) = ltbvrhrcde xfocswedow (aktsveczbr, jkiivvufvo - okftwexzmu)
-
23 Dec 2020
Phase 2
67
(Netupitant 1.33 mg/kg Plus Palonosetron)
pthkesfbdo(tniifydtks) = iuobiuneea bcwcozfxiy (pqkutvqomp, ucuwyeplvx - ohgmnricpb)
-
07 Dec 2020
(Netupitant 4 mg/kg Plus Palonosetron)
pkqqasazmy(liewdgxtno) = bjersjyizn eremdroqpw (xshcawkzps, zigahttgnx - snjmmjdtke)
Not Applicable
-
ldlvourstm(onmqjyxmkc) = Grade 2-3 constipation and any grade of aspartate aminotransferase increase were more frequently observed in 0.75 mg group (38% vs. 58%, p < 0.05; 7% vs. 22%, p < 0.05) jzfycxxrqg (wlblyqarcq )
Positive
22 Nov 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free